PDS Biotechnology Corporation (PDSB)
NASDAQ: PDSB · Real-Time Price · USD
1.080
-0.110 (-9.24%)
Apr 1, 2025, 4:00 PM EDT - Market closed

PDS Biotechnology Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2016
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2016
Selling, General & Admin
13.7615.2812.2410.186.98
Upgrade
Research & Development
22.5727.7629.4311.257.92
Upgrade
Operating Expenses
36.3243.0541.6721.4414.9
Upgrade
Operating Income
-36.32-43.05-41.67-21.44-14.9
Upgrade
Interest Expense
-4.67-4.21-1.32--
Upgrade
Interest & Investment Income
2.512.90.9400.06
Upgrade
EBT Excluding Unusual Items
-38.48-44.35-42.05-21.43-14.85
Upgrade
Pretax Income
-38.48-44.35-42.05-21.43-14.85
Upgrade
Income Tax Expense
-0.87-1.41-1.2-4.52-
Upgrade
Net Income
-37.61-42.94-40.85-16.92-14.85
Upgrade
Net Income to Common
-37.61-42.94-40.85-16.92-14.85
Upgrade
Shares Outstanding (Basic)
3631292617
Upgrade
Shares Outstanding (Diluted)
3631292617
Upgrade
Shares Change (YoY)
17.77%8.23%11.73%52.86%243.98%
Upgrade
EPS (Basic)
-1.03-1.39-1.43-0.66-0.89
Upgrade
EPS (Diluted)
-1.03-1.39-1.43-0.66-0.89
Upgrade
Free Cash Flow
--33.64-25.71-12.49-13.15
Upgrade
Free Cash Flow Per Share
--1.09-0.90-0.49-0.79
Upgrade
EBITDA
-36.26-42.99-41.62-21.43-14.89
Upgrade
D&A For EBITDA
0.060.060.050.010.02
Upgrade
EBIT
-36.32-43.05-41.67-21.44-14.9
Upgrade
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q